Pirtobrutinib results in reversible platelet dysfunction compared to ibrutinib and acalabrutinib

Affiliations

• ¹ Molecular and Clinical Sciences Research Institute, St George's University, Cranmer Terrace, London, United Kingdom; Institute for Cardiovascular and Metabolic Research, School of Biological Sciences, University of Reading, Reading, RG6 6EX. a.bye@sgul.ac.uk.
• ² Institute for Cardiovascular and Metabolic Research, School of Biological Sciences, University of Reading, Reading, RG6 6EX.
• ³ Institute for Cardiovascular and Metabolic Research, School of Biological Sciences, University of Reading, Reading,.
• ⁴ Department of Clinical Haematology, Cancer and Haematology Centre, Churchill Hospital, Oxford University Hospitals NHS Foundation Trust, Oxford, OX3 7LE.
• ⁵ Department of Clinical Haematology, Royal Berkshire Hospital NHS Foundation Trust, Reading, RG1 5AN.
• ⁶ Haematology Late Phase Clinical Trial Unit, Oxford University Hospitals NHS Foundation Trust, Oxford, OX3 7LE.
• ⁷ Department of Clinical Haematology, Oxford University Hospitals NHS Foundation Trust, Oxford, OX3 7LE.
• ⁸ Department of Clinical Haematology, Cancer and Haematology Centre, Churchill Hospital, Oxford University Hospitals NHS Foundation Trust, Oxford,.